Bengaluru, India, February 9, 2026 : Pandorum Technologies, a biotechnology company developing programmable regenerative medicine, has closed a US$18 million Series B financing round to accelerate clinical development of its tunable, exosome-based therapies and expand global manufacturing and operations across the United States, Japan, and the Middle East.
Founded by Dr. Tuhin Bhowmick and Arun Chandru, Pandorum integrates biology, engineering, and computation to develop disease-modifying exosome therapies that reprogram pathological tissue states—such as inflammation and fibrosis—toward functional recovery.
Funding Accelerates Pandorum’s Kuragenx Development and Global Expansion
The Series B capital will support clinical advancement of Kuragenx, Pandorum’s lead asset, while scaling manufacturing capabilities and expanding international operations. Kuragenx targets ocular surface diseases including Stevens–Johnson Syndrome and Neurotrophic Keratitis, and has received U.S. FDA Orphan Drug Designation.
“Just like the Ship of Theseus, the human body is constantly being rebuilt,” said Dr. Tuhin Bhowmick, Co-Founder and CEO of Pandorum Technologies. “Pandorum focuses on restoring biological memory and redefining regenerative medicine at its core. This funding enables us to translate breakthrough science into programmable, disease-modifying therapies—starting with single-tissue repair and scaling to multi-tissue regeneration, aligned with our vision to heal fast and age slow.”
Co-founder Arun Chandru highlighted the global relevance of the company’s work. “Regenerative medicine, especially for corneal blindness, is a global necessity that knows no borders. This milestone reflects the strength of our team and mission.”
Pandorum’s clinical programs are supported by a global network of leading clinicians, including Dr. Virender Singh Sangwan of Dr. Shroff’s Charity Eye Hospital, New Delhi; Dr. Shigeru Kinoshita of Kyoto Prefectural University of Medicine; and Dr. Ramez Haddadin and Dr. Satish Nadig of Northwestern Medicine, Chicago.
To support commercialization, Pandorum has adopted a globally distributed manufacturing strategy. The company has partnered with AGC Biologics in Italy to serve U.S. and European markets and entered a strategic collaboration with Nucelion Therapeutics, a subsidiary of Bharat Biotech, to supply the Asia-Pacific region. Pandorum is also evaluating manufacturing and strategic partnerships in the Middle East.
While ophthalmology remains the company’s primary focus, Pandorum is expanding its tunable regenerative platform to address systemic inflammatory and degenerative diseases affecting the lung, liver, and nervous system.
The funding round was led by Protons Corporate, with participation from Galentic Pharma, marquee investor Ashish Kacholia, Noblevast Advisory, Avinya Fund, the Burman Family, and other investors. Bandana Kankani, advisor and investor at Pandorum, guided the transaction and aligned the investment structure with the company’s long-term value creation strategy.
Pandorum Technologies is a biotechnology company focused on tissue engineering and regenerative medicine, with research operations in India and the United States.
